Short-Chain Fatty Acids

Short-chain fatty acids (SCFAs) are two- to six-carbon saturated fatty acids produced by anaerobic bacterial fermentation of non-digestible carbohydrates in the colon. The three dominant physiological SCFAs are acetate (C2), propionate (C3), and butyrate (C4), produced in an approximate molar ratio of 60:20:20. SCFAs are both a major energy source for colonocytes and an expanding class of signaling molecules influencing systemic metabolism, immunity, and neural function.

Production

Colonic bacteria ferment carbohydrates that escape small-intestinal digestion — resistant starch, inulin, fructooligosaccharides, beta-glucan, pectin, arabinoxylan, and other fermentable fibers — through pathways involving pyruvate as a key intermediate. Different bacterial genera specialize in different SCFA outputs: Bacteroidetes produce predominantly acetate and propionate; Firmicutes (particularly Faecalibacterium prausnitzii, Roseburia, Eubacterium rectale) produce butyrate; Lactobacillus produces lactate that is cross-fed to butyrate-producers. Daily SCFA production in a healthy adult approaches 300-500 mmol, representing approximately 5-10% of host energy intake.

Butyrate and colonocyte metabolism

Butyrate is the preferred energy substrate of colonic epithelial cells, providing 60-70% of colonocyte ATP via mitochondrial beta-oxidation. Butyrate deprivation (as in antibiotic-induced microbial disruption or very-low-fiber diets) produces colonocyte starvation and autophagy, impairing barrier function. This physiology underpins the importance of butyrate-producing bacteria for intestinal health.

Systemic effects

SCFAs absorbed from the colon reach the portal circulation, where acetate and propionate are largely cleared by the liver while a small fraction of butyrate escapes into systemic circulation. Systemic SCFA effects include: (1) GLP-1 and PYY release — via enteroendocrine GPR41/43 stimulation, contributing to satiety; (2) lipid metabolism — acetate serves as substrate for de novo lipogenesis; propionate can suppress hepatic lipogenesis; (3) glucose homeostasis — propionate signals intestinal gluconeogenesis, contributing to insulin sensitivity; (4) immune function — SCFAs promote regulatory T-cell differentiation via HDAC inhibition and GPR43 signaling, contributing to anti-inflammatory tone; (5) neural signaling — SCFA influence on vagal afferents and, in some contexts, direct CNS crossing via monocarboxylate transporters.

Signaling receptors

SCFAs are endogenous ligands for at least two G-protein-coupled receptors: GPR43 (FFAR2) — expressed on enteroendocrine L-cells, adipocytes, and immune cells; activated by acetate and propionate; mediates GLP-1 release and inflammatory modulation; GPR41 (FFAR3) — expressed on enteroendocrine cells and sympathetic ganglia; activated by propionate and butyrate; contributes to PYY release and sympathetic tone. Butyrate is additionally a direct class I and II histone deacetylase (HDAC) inhibitor at physiological colonic concentrations, affecting chromatin structure and gene expression in colonocytes and immune cells.

Measurement

Fecal SCFA concentrations can be measured by gas chromatography or HPLC and reflect both production and absorption — typical values 80-150 mmol/kg wet feces. Plasma SCFA concentrations are low (acetate 50-200 µM; propionate and butyrate under 10 µM) due to rapid hepatic clearance. Stable-isotope tracer studies are used to quantify production rates in research settings.

Dietary modulation

SCFA production is increased by fermentable fiber intake: resistant starch (green bananas, cooled rice, cooled potatoes), inulin (chicory, Jerusalem artichoke, onions, garlic), beta-glucan (oats, barley), psyllium, and legume-derived oligosaccharides. The US Western diet, low in fermentable fiber, produces relatively low SCFA output compared to high-fiber traditional diets (rural African, vegetarian, Mediterranean). Sonnenburg and others have hypothesized that "MACD" — microbiota-accessible carbohydrate deficiency — in modern diets contributes to chronic disease via reduced SCFA signaling and gut barrier dysfunction.

Therapeutic interest

Exogenous SCFA administration has been studied: butyrate enemas for ulcerative colitis (modest efficacy in pouchitis and distal UC); oral sodium butyrate supplements (questionable colonic delivery); acetate/propionate inhalation for asthma (mouse models). Fiber-based strategies that increase endogenous SCFA production remain the most reliable approach.